Here are the DEF 14A proxy statements from Agios Pharmaceuticals, Inc. (AGIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AGIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGIO filings page.
Agios Pharmaceuticals is holding its 2026 Annual Meeting of Stockholders as a fully virtual webcast on June 18, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on April 21, 2026, when 59,471,609 common shares were outstanding, may vote.
Items up for vote include electing three Class I directors to terms ending in 2029, an advisory say‑on‑pay vote on executive compensation, approval of an amendment to the 2023 Stock Incentive Plan to increase available shares, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. A majority of outstanding shares, about 29,735,805, is needed for a quorum. The company uses internet “notice and access” and emphasizes ESG initiatives, flexible work culture and extensive governance structures.